

Supplementary Fig. 2. Characterization of *LSL-Kras*^{G12D} × Mx1-*Cre*-induced leukemia in *Nox2*^{-/-} mice. (A-C) *Nox2*^{-/-}LSL-*Kras*^{G12D} × *Nox2*^{-/-}Mx1-*Cre* (*Nox2*^{-/-}M-*Kras*^{G12D}; blue lines) mice and wild-type (*Nox2*^{-/-}*Kras*^{WT}; black lines) mice were injected with pIpC at the time point w₀. Peripheral blood was collected at 3, 5 and 7 weeks (w3-7) after pIpC injection. The peripheral blood of *Nox2*^{-/-}M-*Kras*^{G12D} mice showed a progressive increase in white blood cell (WBC) counts (A), along with a reduction of red blood cell (RBC) counts (B) and hemoglobin levels (C; n=8 for *Nox2*^{-/-}*Kras*^{WT} at each time point, n=8 for *Nox2*^{-/-}M-*Kras*^{G12D} at each time point except n=2 at w7). (D) Number of splenocytes isolated from endpoint *Nox2*^{-/-}M-*Kras*^{G12D} mice (blue, n=6). The splenocyte counts from *Nox2*^{-/-}*Kras*^{WT} mice (black, n=6) are shown for comparison (*t*-test). (E) Frequency of CD11b⁺-infiltrating cells among live cells in the spleens of endpoint *Nox2*^{-/-}M-*Kras*^{G12D} mice (blue, n=5) and *Nox2*^{-/-}*Kras*^{WT} mice (black, n=5) (*t*-test). *p<0.05. **p<0.01. ***p<0.001.